BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23598982)

  • 1. Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.
    Pal SK; Vogelzang NJ
    Clin Adv Hematol Oncol; 2013 Mar; 11(3):146-55. PubMed ID: 23598982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy in metastatic renal cell cancer.
    Ravaud A; Gross-Goupil M; Bellmunt J
    Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
    Wright I; Kapoor A
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
    Diamond E; Molina AM; Carbonaro M; Akhtar NH; Giannakakou P; Tagawa ST; Nanus DM
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):518-26. PubMed ID: 26321263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
    Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
    Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for the design of future clinical trials in metastatic renal cell carcinoma.
    Escudier B; Heng DY; Smyth-Medina A; Porta C
    Clin Genitourin Cancer; 2014 Feb; 12(1):1-12. PubMed ID: 24220221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.
    González Larriba JL; Espinosa E; García Carbonero I; García-Donas J; López M; Meana A; Puente J; Bellmunt J
    Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S11-7. PubMed ID: 22674353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives in the treatment of metastatic renal cell carcinoma.
    Barrière J; Hoch B; Ferrero JM
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review.
    Porta C; Szczylik C; Escudier B
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):323-37. PubMed ID: 21733715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Systemic therapy for metastatic renal cell carcinoma].
    Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
    Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine.
    Neuzillet Y; Culine S; Patard JJ
    Int J Urol; 2009 Nov; 16(11):855-61. PubMed ID: 19674168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.
    Bex A; Gore M; Mulders P; Sternberg CN
    BJU Int; 2012 Nov; 110(9):1289-300. PubMed ID: 22624610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy in the treatment of metastatic renal cell cancer.
    Di Lorenzo G; Scagliarini S; Di Napoli M; Scognamiglio F; Rizzo M; Carteni' G
    Oncology; 2009; 77 Suppl 1():122-31. PubMed ID: 20130440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.